261 related articles for article (PubMed ID: 26796737)
1. The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.
König L; Kasimir-Bauer S; Hoffmann O; Bittner AK; Wagner B; Manvailer LF; Schramm S; Bankfalvi A; Giebel B; Kimmig R; Horn PA; Rebmann V
Hum Immunol; 2016 Sep; 77(9):791-9. PubMed ID: 26796737
[TBL] [Abstract][Full Text] [Related]
2. High Amounts of Total and Extracellular Vesicle-Derived Soluble HLA-G are Associated with HLA-G 14-bp Deletion Variant in Women with Embryo Implantation Failure.
Nardi Fda S; Slowik R; Michelon T; Manvailer LF; Wagner B; Neumann J; Horn P; Bicalho Mda G; Rebmann V
Am J Reprod Immunol; 2016 Jun; 75(6):661-71. PubMed ID: 26959830
[TBL] [Abstract][Full Text] [Related]
3. Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages.
Kirana C; Ruszkiewicz A; Stubbs RS; Hardingham JE; Hewett PJ; Maddern GJ; Hauben E
Int J Cancer; 2017 Jun; 140(11):2577-2586. PubMed ID: 28233298
[TBL] [Abstract][Full Text] [Related]
4. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer.
Chen HX; Lin A; Shen CJ; Zhen R; Chen BG; Zhang X; Cao FL; Zhang JG; Yan WH
Hum Immunol; 2010 Sep; 71(9):892-8. PubMed ID: 20547193
[TBL] [Abstract][Full Text] [Related]
6. Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary.
Schwich E; Hò GT; LeMaoult J; Bade-Döding C; Carosella ED; Horn PA; Rebmann V
Front Immunol; 2020; 11():2046. PubMed ID: 32973812
[TBL] [Abstract][Full Text] [Related]
7. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease.
Borghi A; Fogli E; Stignani M; Melchiorri L; Altieri E; Baricordi O; Rizzo R; Virgili A
Arch Dermatol Res; 2008 Nov; 300(10):551-9. PubMed ID: 18797896
[TBL] [Abstract][Full Text] [Related]
8. Increased plasmatic soluble HLA-G levels in endometrial cancer.
Ben Yahia H; Babay W; Bortolotti D; Boujelbene N; Laaribi AB; Zidi N; Kehila M; Chelbi H; Boudabous A; Mrad K; Mezlini A; Di Luca D; Ouzari HI; Rizzo R; Zidi I
Mol Immunol; 2018 Jul; 99():82-86. PubMed ID: 29730546
[TBL] [Abstract][Full Text] [Related]
9. Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.
Morandi F; Pozzi S; Carlini B; Amoroso L; Pistoia V; Corrias MV
J Immunol Res; 2016; 2016():7465741. PubMed ID: 27610393
[TBL] [Abstract][Full Text] [Related]
10. Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients.
Hoffmann O; Wormland S; Bittner AK; Hölzenbein J; Schwich E; Schramm S; Rohn H; Horn PA; Kimmig R; Kasimir-Bauer S; Rebmann V
Front Immunol; 2023; 14():1188030. PubMed ID: 37283737
[TBL] [Abstract][Full Text] [Related]
11. Implication of Soluble HLA-G and HLA-G +3142G/C Polymorphism in Breast Cancer Patients Receiving Adjuvant Therapy in Tanzania.
Adolf IC; Akan G; Mselle TF; Dharsee N; Namkinga LA; Atalar F
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3465-3472. PubMed ID: 31759373
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.
Pan YQ; Ruan YY; Peng JB; Han QY; Zhang X; Lin A; Yan WH
Hum Immunol; 2016 Apr; 77(4):317-24. PubMed ID: 26788811
[TBL] [Abstract][Full Text] [Related]
13. Association of HLA-G +3142 C>G polymorphism and breast cancer in Tunisian population.
Zidi I; Dziri O; Zidi N; Sebai R; Boujelebene N; Ben Hassine A; Ben Yahia H; Laaribi AB; Babay W; Rifi H; Mezlini A; Chelbi H
Immunol Res; 2016 Aug; 64(4):961-8. PubMed ID: 26754763
[TBL] [Abstract][Full Text] [Related]
14. Soluble human leukocyte antigen-g and its insertion/deletion polymorphism in papillary thyroid carcinoma: novel potential biomarkers of disease?
Dardano A; Rizzo R; Polini A; Stignani M; Tognini S; Pasqualetti G; Ursino S; Colato C; Ferdeghini M; Baricordi OR; Monzani F
J Clin Endocrinol Metab; 2012 Nov; 97(11):4080-6. PubMed ID: 22930786
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of high circulating sHLA-G in ovarian carcinoma.
Babay W; Boujelbene N; Ben Yahia H; Bortolotti D; Zemni I; Ouzari HI; Chelbi H; Mezlini A; Rizzo R; Zidi I
HLA; 2021 Oct; 98(4):357-365. PubMed ID: 34272932
[TBL] [Abstract][Full Text] [Related]
16. Elevation of HLA-G-expressing DC-10 cells in patients with gastric cancer.
Xu DP; Shi WW; Zhang TT; Lv HY; Li JB; Lin A; Yan WH
Hum Immunol; 2016 Sep; 77(9):800-4. PubMed ID: 26773190
[TBL] [Abstract][Full Text] [Related]
17. The paradox of high availability and low recognition of soluble HLA-G by LILRB1 receptor in rheumatoid arthritis patients.
Veit TD; Chies JA; Switala M; Wagner B; Horn PA; Busatto M; Brenol CV; Tavares Brenol JC; Machado Xavier R; Rebmann V
PLoS One; 2015; 10(4):e0123838. PubMed ID: 25853899
[TBL] [Abstract][Full Text] [Related]
18. Systematic Evaluation of
Rebmann V; Schwich E; Michita RT; Grüntkemeier L; Bittner AK; Rohn H; Horn PA; Hoffmann O; Kimmig R; Kasimir-Bauer S
Front Immunol; 2021; 12():817132. PubMed ID: 35095919
[TBL] [Abstract][Full Text] [Related]
19. Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy.
Provatopoulou X; Kalogera E; Sagkriotis A; Zagouri F; Nonni A; Zografos GC; Gounaris A
Anticancer Res; 2012 Mar; 32(3):1021-6. PubMed ID: 22399626
[TBL] [Abstract][Full Text] [Related]
20. Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation.
Rebmann V; Bartsch D; Wunsch A; Möllenbeck P; Golda T; Viebahn R; Grosse-Wilde H
Hum Immunol; 2009 Dec; 70(12):995-9. PubMed ID: 19651178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
